Fennec Pharmaceuticals Inc. (FENC) stock
FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.33−0.25 (-1.84%)
Close on Nov 18, 2026Market cap $467.45MP/E –Yield –
Fennec Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Fennec Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$1.13M. For fiscal 2025 it was -$6.28M, down 344.6% from the year before. The highest annual figure on record is $2.57M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.28M | -344.6% |
| FY2024 | Dec 31, 2024 | $2.57M | – |
| FY2023 | Dec 31, 2023 | -$12.77M | – |
| FY2022 | Dec 31, 2022 | -$22.59M | – |
| FY2021 | Dec 31, 2021 | -$17.22M | – |
| FY2020 | Dec 31, 2020 | -$17.89M | – |
| FY2019 | Dec 31, 2019 | -$13.01M | – |
| FY2018 | Dec 31, 2018 | -$10.41M | – |
| FY2017 | Dec 31, 2017 | -$6.95M | – |
| FY2016 | Dec 31, 2016 | -$2.87M | – |
| FY2015 | Dec 31, 2015 | -$1.89M | – |
| FY2014 | Dec 31, 2014 | -$2.88M | – |
| FY2013 | Dec 31, 2013 | -$1.93M | – |
| FY2012 | Dec 31, 2012 | -$3.62M | – |
| FY2011 | Dec 31, 2011 | -$3.44M | – |
| FY2010 | Dec 31, 2010 | -$4.60M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.74M | – |
| Q1 FY2026 | Mar 31, 2026 | -$119.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.55M | – |
| Q3 FY2025 | Sep 30, 2025 | -$189.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$808.00K | -105.9% |
| Q4 FY2024 | Dec 31, 2024 | -$934.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.04M | – |
| Q1 FY2024 | Mar 31, 2024 | $13.74M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.02M | – |
| Q2 FY2023 | Jun 30, 2023 | -$4.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.27M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.14M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.90M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.01M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.55M | – |
| Q4 FY2021 | Dec 31, 2021 | -$4.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.17M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.92M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.92M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.35M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.86M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.85M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.84M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.65M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.86M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.81M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.68M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.11M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.85M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.67M | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.79M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.52M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.19M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.48M | – |
| Q1 FY2017 | Mar 31, 2017 | -$771.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.15M | – |
| Q3 FY2016 | Sep 30, 2016 | -$564.00K | – |
See a number that looks wrong?